Finally, new awareness of the metabolic profiles of patients with AIP, mostly characterized by alterations in glucose metabolism, mitochondrial dysfunction, and metabolic reprogramming, is paving the way for the introduction of liver-targeted insulin and/or its mimicking agents in order to improve the efficacy of glucose therapy. The gene discussed is INS; the disease is autoimmune pancreatitis.